Polunovsky (23 risultati)

Perfeziona la tua ricerca

  • Libri (23)

a

Fascia di prezzo personalizzata (EUR)

a

  • Lingua: Inglese

    Editore: Humana, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 81,64

    EUR 6,80 spedizione 
    Spedito da Italia a U.S.A.

    Quantità: 1 disponibili

    Condizione: new.

  • Lingua: Inglese

    Editore: Humana, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Ria Christie Collections, Uxbridge, Regno UnitoRia Christie Collections

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 227,07

    EUR 13,17 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. In English.

  • Lingua: Inglese

    Editore: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura

    Da: Ria Christie Collections, Uxbridge, Regno UnitoRia Christie Collections

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 227,07

    EUR 13,17 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. In English.

  • Altre immagini

    Lingua: Inglese

    Editore: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura

    Da: preigu, Osnabrück, Germaniapreigu

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 184,95

    EUR 70,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 5 disponibili

    Taschenbuch. Condizione: Neu. mTOR Pathway and mTOR Inhibitors in Cancer Therapy | Vitaly A. Polunovsky (u. a.) | Taschenbuch | Cancer Drug Discovery and Development | xii | Englisch | 2012 | Humana | EAN 9781617796944 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

  • Lingua: Inglese

    Editore: Humana Press Inc., 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura

    Da: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 251,96

    EUR 9,50 spedizione 
    Spedito da Irlanda a U.S.A.

    Quantità: 15 disponibili

    Condizione: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL; MMG; PSF. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 17. Weight in Grams: 486. . 2012. Paperback. . . . .

  • Lingua: Inglese

    Editore: Humana Press Inc., 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandaKennys Bookshop and Art Galleries Ltd.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 253,22

    EUR 9,50 spedizione 
    Spedito da Irlanda a U.S.A.

    Quantità: 15 disponibili

    Condizione: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 695. . 2010. Hardback. . . . .

  • Lingua: Inglese

    Editore: Humana Press, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Buchpark, Trebbin, GermaniaBuchpark

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Usato - Ottimo

    EUR 158,31

    EUR 105,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Condizione: Sehr gut. Zustand: Sehr gut | Seiten: 316 | Sprache: Englisch | Produktart: Bücher | The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

  • Lingua: Inglese

    Editore: Humana Press, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura

    Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 304,51

    EUR 11,66 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 2 disponibili

    Paperback. Condizione: Brand New. 316 pages. 9.25x6.10x0.75 inches. In Stock.

  • Lingua: Inglese

    Editore: Humana Pr Inc, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 305,95

    EUR 14,58 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 2 disponibili

    Hardcover. Condizione: Brand New. 1st edition. 301 pages. 9.25x6.25x1.00 inches. In Stock.

  • Lingua: Inglese

    Editore: Humana Press Inc., 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura

    Da: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 318,29

    EUR 9,14 spedizione 
    Spedito in U.S.A.

    Quantità: 15 disponibili

    Condizione: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL; MMG; PSF. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 17. Weight in Grams: 486. . 2012. Paperback. . . . . Books ship from the US and Ireland.

  • Lingua: Inglese

    Editore: Humana Press Inc., 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Kennys Bookstore, Olney, MD, U.S.A.Kennys Bookstore

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 319,87

    EUR 9,14 spedizione 
    Spedito in U.S.A.

    Quantità: 15 disponibili

    Condizione: New. Editor(s): Polunovsky, V. A.; Houghton, Peter J. Series: Cancer Drug Discovery and Development. Num Pages: 304 pages, 3 colour tables, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 23. Weight in Grams: 695. . 2010. Hardback. . . . . Books ship from the US and Ireland.

  • Lingua: Inglese

    Editore: Humana, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato

    Da: Mispah books, Redhill, SURRE, Regno UnitoMispah books

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Usato - Come nuovo

    EUR 333,92

    EUR 29,15 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibili

    Hardcover. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Condizione: Usato - Buono

    EUR 178,45

    EUR 8,70 spedizione 
    Spedito in U.S.A.

    Quantità: 1 disponibili

    Aggiungi al carrello

    Hardcover. Condizione: Good. In Russian. Polunovsky, Albert Grigorievich. Construction of vertical drainage piles in the construction of highways on weak ground. Moscow: 1974. All images are for identification of editions only. Several books of the same edition may be available. Please feel free to request photos of available books.SKU7329055.

  • Lingua: Inglese

    Editore: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura
    • Print on Demand

    Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 166,29

    EUR 5,50 spedizione 
    Spedito da Italia a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: new. Questo è un articolo print on demand.

  • Lingua: Inglese

    Editore: Humana, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato
    • Print on Demand

    Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 166,29

    EUR 6,80 spedizione 
    Spedito da Italia a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: new. Questo è un articolo print on demand.

  • Lingua: Inglese

    Editore: Humana Press, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura
    • Print on Demand

    Da: moluna, Greven, Germaniamoluna

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 180,07

    EUR 48,99 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding .

  • Lingua: Inglese

    Editore: Humana Press, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato
    • Print on Demand

    Da: moluna, Greven, Germaniamoluna

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 180,07

    EUR 48,99 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding .

  • Lingua: Inglese

    Editore: Humana Press Okt 2012, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura
    • Print on Demand

    Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 213,99

    EUR 23,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 2 disponibili

    Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics. 316 pp. Englisch.

  • Lingua: Inglese

    Editore: Humana Press Aug 2010, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato
    • Print on Demand

    Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 213,99

    EUR 23,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 2 disponibili

    Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics. 316 pp. Englisch.

  • Lingua: Inglese

    Editore: Humana Press, Humana Aug 2010, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato
    • Print on Demand

    Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 213,99

    EUR 60,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Buch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 316 pp. Englisch.

  • Lingua: Inglese

    Editore: Humana Press, Humana Press Okt 2012, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura
    • Print on Demand

    Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 213,99

    EUR 60,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment ¿ targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 316 pp. Englisch.

  • Lingua: Inglese

    Editore: Humana, 2012

    1617796948 / 9781617796944

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Brossura
    • Print on Demand

    Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 297,68

    EUR 30,50 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.

  • Lingua: Inglese

    Editore: Humana, 2010

    1603272704 / 9781603272704

    Serie: Libro 64 di 96 - Cancer Drug Discovery and Development

    • Rilegato
    • Print on Demand

    Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 297,68

    EUR 30,50 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibili

    Buch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The main objective of this book is to provide an up-to-date survey of the rapidly advancing eld of cancer therapy. Moreover, since our knowledge in this area rapidly evolves, some data have got obsolete during the process of book editing. Our understanding of the mechanisms involved in cancer genesis and progression underwent unprecedented expansion during the last decade, opening a new era of cancer treatment - targeted therapy. The surge in this area results in no small part from studies conducted jointly by basic health scientists and clinical investigators. It is our hope that this book will help foster even further collaboration between investigators in these two disciplines. The target of rapamycin (TOR) was rst identi ed in Saccharomyces cerevisiae and subsequently in mammals (mTOR) as a conserved atypical serine/threonine kinase. In mammalian cells, mTOR exists in at least two multi-protein complexes that have critical roles in regulating cellular homeostasis and survival. As with many other areas of science, discovery of TOR signaling was fortuitous. Rapamycin was isolated as a product of the soil bacteria Streptomyces hygroscopicus, identi ed in a soil sample taken from the island of Rapa Nui (Easter Island). Rapamycin was rst discovered to be a potent antifungal agent and next as an immune suppressive drug. It was only later that it was found to be active as an antitumor agent in non-clinical models; although it was not developed for this indication. The history of rapamycin presents one of the rst examples of chemical genetics.